Oxytocin Antagonist in Patients With Repeated Failure of Implantation

AZ Jan Palfijn Gent138 enrolled

Overview

In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

138

Conditions

Implantation Failure

Interventions

AtosibanDRUG

Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.

placeboDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 38 Years

Medical Language ↔ Plain English

Inclusion Criteria: * IVF/ ICSI patients below 38 years * 2e to 6e IVF-cycle Exclusion Criteria: * patients with endocrinological diseases or problems

Locations (1)

AZ Jan Palfijn

Ghent, Oost-vlaanderen, Belgium

Outcomes

Primary Outcomes

implantation rate

the number of patients that show a positive serum blood pregnancy test

Time frame: 16 days from eggretrieval

Secondary Outcomes

pregnancy rate

The number of patients with an ongoing first trimester pregnancy

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.